mbiomics designs and develops complex microbiome-based therapeutics aimed at altering the treatment paradigm for severe and chronic diseases. The company utilizes proprietary precision analytics and patient insights to build pipelines of rationally selected microbial communities for indication-specific treatment. This approach seeks to restore healthy gut microbial ecosystems by accessing their full immunological and metabolic potential to overcome disease.
Funding
$13.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current microbiome-based therapeutics face challenges due to patient heterogeneity in severe and chronic diseases, leading to inconsistent treatment outcomes. Traditional approaches often fail to account for the complex interplay of microbial strains within the gut ecosystem, limiting their ability to restore healthy microbial balance effectively.
Solution
mbiomics develops rationally selected microbial consortia designed to address patient heterogeneity and restore healthy gut ecosystems for the treatment of severe and chronic diseases. The company utilizes a proprietary fluorescence microscopy-based profiling technology to precisely analyze the in vivo microbiome composition of patient samples. This technology enables the identification of optimal microbial strains for creating tailored consortia with disease-specific activity and improved safety profiles, effectively recapitulating the clinical efficacy of fecal transplants through designed complex consortia. By leveraging precision analytics and patient insights, mbiomics aims to unlock the full immunological and metabolic potential of the gut microbiome to overcome disease.
Target Audience
The primary target audience includes patients with severe and chronic diseases, as well as clinical partners and researchers seeking advanced microbiome-based therapeutic solutions.
Features
- Proprietary fluorescence microscopy-based profiling technology for precise microbiome analysis
- Multiplexing panels for rapid and accurate deciphering of in vivo microbiome composition
- Identification of optimal microbial strains for tailored disease-targeting properties
- Design of complex consortia to restore healthy microbial ecosystems
- Disease-specific activity and improved safety profiles compared to traditional approaches